» Articles » PMID: 32722715

Estimation of SARS-CoV-2 Mortality During the Early Stages of an Epidemic: A Modeling Study in Hubei, China, and Six Regions in Europe

Overview
Journal PLoS Med
Specialty General Medicine
Date 2020 Jul 30
PMID 32722715
Citations 88
Authors
Affiliations
Soon will be listed here.
Abstract

Background: As of 16 May 2020, more than 4.5 million cases and more than 300,000 deaths from disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been reported. Reliable estimates of mortality from SARS-CoV-2 infection are essential for understanding clinical prognosis, planning healthcare capacity, and epidemic forecasting. The case-fatality ratio (CFR), calculated from total numbers of reported cases and reported deaths, is the most commonly reported metric, but it can be a misleading measure of overall mortality. The objectives of this study were to (1) simulate the transmission dynamics of SARS-CoV-2 using publicly available surveillance data and (2) infer estimates of SARS-CoV-2 mortality adjusted for biases and examine the CFR, the symptomatic case-fatality ratio (sCFR), and the infection-fatality ratio (IFR) in different geographic locations.

Method And Findings: We developed an age-stratified susceptible-exposed-infected-removed (SEIR) compartmental model describing the dynamics of transmission and mortality during the SARS-CoV-2 epidemic. Our model accounts for two biases: preferential ascertainment of severe cases and right-censoring of mortality. We fitted the transmission model to surveillance data from Hubei Province, China, and applied the same model to six regions in Europe: Austria, Bavaria (Germany), Baden-Württemberg (Germany), Lombardy (Italy), Spain, and Switzerland. In Hubei, the baseline estimates were as follows: CFR 2.4% (95% credible interval [CrI] 2.1%-2.8%), sCFR 3.7% (3.2%-4.2%), and IFR 2.9% (2.4%-3.5%). Estimated measures of mortality changed over time. Across the six locations in Europe, estimates of CFR varied widely. Estimates of sCFR and IFR, adjusted for bias, were more similar to each other but still showed some degree of heterogeneity. Estimates of IFR ranged from 0.5% (95% CrI 0.4%-0.6%) in Switzerland to 1.4% (1.1%-1.6%) in Lombardy, Italy. In all locations, mortality increased with age. Among individuals 80 years or older, estimates of the IFR suggest that the proportion of all those infected with SARS-CoV-2 who will die ranges from 20% (95% CrI 16%-26%) in Switzerland to 34% (95% CrI 28%-40%) in Spain. A limitation of the model is that count data by date of onset are required, and these are not available in all countries.

Conclusions: We propose a comprehensive solution to the estimation of SARS-Cov-2 mortality from surveillance data during outbreaks. The CFR is not a good predictor of overall mortality from SARS-CoV-2 and should not be used for evaluation of policy or comparison across settings. Geographic differences in IFR suggest that a single IFR should not be applied to all settings to estimate the total size of the SARS-CoV-2 epidemic in different countries. The sCFR and IFR, adjusted for right-censoring and preferential ascertainment of severe cases, are measures that can be used to improve and monitor clinical and public health strategies to reduce the deaths from SARS-CoV-2 infection.

Citing Articles

Bayesian workflow for time-varying transmission in stratified compartmental infectious disease transmission models.

Bouman J, Hauser A, Grimm S, Wohlfender M, Bhatt S, Semenova E PLoS Comput Biol. 2024; 20(4):e1011575.

PMID: 38683878 PMC: 11081492. DOI: 10.1371/journal.pcbi.1011575.


Estimates of COVID-19 Cases across Four Canadian Provinces.

Benatia D, Godefroy R, Lewis J Can Public Policy. 2024; 46(Suppl 3):S203-S216.

PMID: 38630004 PMC: 8228716. DOI: 10.3138/cpp.2020-035.


SARS-CoV-2 variant identification using a genome tiling array and genotyping probes.

Shimada R, Alden E, Hoff K, Ding X, Sun J, Halasz A Per Med. 2023; 20(1):13-25.

PMID: 36974726 PMC: 10350312. DOI: 10.2217/pme-2022-0013.


Evolution of antibody profiles against SARS-CoV-2 in experienced and naïve vaccinated elderly people.

Sanz-Munoz I, Lopez-Mongil R, Sanchez-Martinez J, Sanchez-de Prada L, Gonzalez M, Perez-SanJose D Front Immunol. 2023; 14:1128302.

PMID: 36911673 PMC: 9992205. DOI: 10.3389/fimmu.2023.1128302.


Pyfectious: An individual-level simulator to discover optimal containment policies for epidemic diseases.

Mehrjou A, Soleymani A, Abyaneh A, Bhatt S, Scholkopf B, Bauer S PLoS Comput Biol. 2023; 19(1):e1010799.

PMID: 36689461 PMC: 9894541. DOI: 10.1371/journal.pcbi.1010799.


References
1.
Wang C, Horby P, Hayden F, Gao G . A novel coronavirus outbreak of global health concern. Lancet. 2020; 395(10223):470-473. PMC: 7135038. DOI: 10.1016/S0140-6736(20)30185-9. View

2.
Bi Q, Wu Y, Mei S, Ye C, Zou X, Zhang Z . Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: a retrospective cohort study. Lancet Infect Dis. 2020; 20(8):911-919. PMC: 7185944. DOI: 10.1016/S1473-3099(20)30287-5. View

3.
Verity R, Okell L, Dorigatti I, Winskill P, Whittaker C, Imai N . Estimates of the severity of coronavirus disease 2019: a model-based analysis. Lancet Infect Dis. 2020; 20(6):669-677. PMC: 7158570. DOI: 10.1016/S1473-3099(20)30243-7. View

4.
Zhang J, Klepac P, Read J, Rosello A, Wang X, Lai S . Patterns of human social contact and contact with animals in Shanghai, China. Sci Rep. 2019; 9(1):15141. PMC: 6805924. DOI: 10.1038/s41598-019-51609-8. View

5.
Linton N, Kobayashi T, Yang Y, Hayashi K, Akhmetzhanov A, Jung S . Incubation Period and Other Epidemiological Characteristics of 2019 Novel Coronavirus Infections with Right Truncation: A Statistical Analysis of Publicly Available Case Data. J Clin Med. 2020; 9(2). PMC: 7074197. DOI: 10.3390/jcm9020538. View